Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Novel Immunotherapeutics Against Lgr5 To Target Multiple Cancer Types.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Novel Immunotherapeutics Against Lgr5 To Target Multiple Cancer Types.

Related Experiment Video

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Novel immunotherapeutics against LGR5 to target multiple cancer types.

Hung-Chang Chen^1,2, Nico Mueller¹, Katherine Stott³

¹University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.

EMBO Molecular Medicine

|August 21, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A novel antibody targeting Leucine-rich repeat-containing G-protein coupled Receptor 5 (LGR5) shows promise. This antibody, α-LGR5, effectively targets various cancers and serves as a foundation for developing potent immunotherapies.

Keywords:

ADC BiTE CAR Cancer Immunotherapeutics

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Oncology
Immunology
Biotechnology

Background:

Leucine-rich repeat-containing G-protein coupled Receptor 5 (LGR5) is overexpressed in several aggressive cancers, including colorectal cancer (CRC), hepatocellular carcinoma (HCC), and pre-B acute lymphoblastic leukemia (pre-B-ALL).
Targeting LGR5 presents a potential therapeutic strategy for these malignancies.

Purpose of the Study:

To develop and validate a specific antibody against the extracellular domain of human LGR5 (α-LGR5).
To evaluate the therapeutic potential of α-LGR5 in various formats, including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cells, for targeting LGR5-expressing cancers.

Main Methods:

Development and validation of a specific antibody (α-LGR5) targeting human LGR5.
Generation of α-LGR5-based immunotherapeutic modalities: antibody-drug conjugate (α-LGR5-ADC), bispecific T-cell engager (α-LGR5-BiTE), and chimeric antigen receptor (α-LGR5-CAR) T-cells.

In vitro and in vivo efficacy studies using cancer cell lines and a murine model of human pre-B-ALL.

Main Results:

α-LGR5 detected LGR5 overexpression in over 90% of CRC, HCC, and pre-B-ALL tumor cells.
α-LGR5-ADC demonstrated potent in vitro and in vivo anti-tumor efficacy in a pre-B-ALL murine model, reducing tumor burden significantly.
α-LGR5-BiTE and α-LGR5-CAR T-cells also showed specific cancer cell killing and reduced tumor burden in vivo.

Conclusions:

α-LGR5 is a versatile antibody that can be utilized as a research tool, biomarker, and a foundational component for developing novel immunotherapies.
The developed α-LGR5-based therapeutics offer a promising portfolio for targeting a wide range of LGR5-expressing cancers.